This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Zumutor Biologics Inc.
Zumutor Biologics Inc.
Incyte Corporation
Immunitas Therapeutics
Nurix Therapeutics, Inc.
Arcus Biosciences, Inc.
Shattuck Labs, Inc.
Seagen Inc.
Celldex Therapeutics
Stanford University
CytomX Therapeutics
Celgene
City of Hope Medical Center
Eastern Cooperative Oncology Group
Sorrento Therapeutics, Inc.
Celgene
AbbVie
Novartis
Incyte Corporation
University of Wisconsin, Madison
Incyte Corporation
National Institutes of Health Clinical Center (CC)
European Organisation for Research and Treatment of Cancer - EORTC
Wake Forest University Health Sciences
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)
National Cancer Institute (NCI)
INSYS Therapeutics Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center